Innate Pharma S.A (IPHA) Value Adjusted for Debt and Cash

Innate Pharma S.A (IPHA) - corporate logo

The market capitalization trend for Innate Pharma S.A. (IPHA) on the GURU.Markets platform is 175.96, supported by a stable moat derived from its innate immunity activation platform and licensing fees. The French developer dictates payment terms thanks to exclusive patents and alliances with market leaders. High barriers to entry are created by antibody patents and stringent oversight from the EMA and FDA.

IPHA (Innate Pharma S.A.) Total Company Value history from 11/23/2025 to 10/28/2026

Innate Pharma S.A. - analytical breakdowns and key metrics (IPHA)

- price and consensus price forecast:
Quote Chart Innate Pharma SA|IPHA - Analyst Consensus Forecast
- market capitalization data:
Market Value Innate Pharma|IPHA - Enterprise Value
- book capitalization data:
Book Value per Share Innate Pharma|IPHA - Company Book Value|Market-to-Book Ratio innate-pharma.com|IPHA - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio innate-pharma.com|IPHA - Company Debts|Debts to Book Value Innate Pharma
Fundamental valuation:Innate Pharma SA (IPHA)
Original product of Innate Pharma

Enterprise value represents the total acquisition cost of an asset, combining market capitalization and net debt, which allows for an assessment of the actual costs of buying out a business. By analyzing the aggregate valuation of Innate Pharma S.A. (IPHA), an investor can see how high R&D expenditures on laboratories are balanced by strategic partnerships, determining a fair value threshold relative to capital drawdown risks.

Competitors of Innate Pharma S.A. (IPHA)

Full Business Value ImmunityBio Inc IBRX|Enterprise Value Immunocore PLC (IMCR)|JANX - Value Adjusted for Debt and Cash|RCUS: Enterprise Value|ZYME (zymeworks.com) - Enterprise Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)